Skip to Main Content
Home Books Internal Medicine: A Guide to Clinical Therapeutics

Chapter 35. HIV Infection and AIDS

Elizabeth Hand; Kathryn Dzintars

Incidence of HIV Infection & AIDS: 56,000 individuals in U.S. infected annually: 21% with HIV unaware of HIV + status; 31% progress to AIDS w/in 12mo of HIV diagnosis; strongly consider testing in those with risk factors: male-to-male sexual contact, IV drug use, heterosexual contact (http://www.cdc.gov/hiv/topics/surveillance/resources/reports/; JAMA 2008;300:520)

Table 35-1 Common Presenting Signs & Symptoms of Acute HIV Infection
View Table||Download (.pdf)
Table 35-1 Common Presenting Signs & Symptoms of Acute HIV Infection

Occurred in ≥50% of Patients

Occurred in ≤50% of Patients

Fever, fatigue, rash, HA, lymphadenopathy, pharyngitis, myalgia or arthralgias, night sweats, N/V, or diarrhea

Aseptic meningitis, oral ulcers, genital ulcers, thrombocytopenia, leukopenia, elevated hepatic enzyme levels

  • Signs & symptoms of acute HIV infection present w/in days to weeks of viral exposure & typically last <14d (N Engl J Med 1998;339:33)
  • Consider acute HIV infection in persons presenting with STD; differential diagnosis if unexplained, severe febrile illness
  • Newly diagnosed with HIV (N Engl J Med 2005;353:1702): care primarily based on sx; counsel patient regarding disease process/progression to AIDS; limit risk of secondary transmission; ensure proper support established; perform baseline lab testing prior to HIV management

Table 35-2 Recommended Baseline Tests at Entry into Care
View Table||Download (.pdf)
Table 35-2 Recommended Baseline Tests at Entry into Care

HIV antibody testing

CD4 T-cell count

Plasma HIV RNA (viral load)

Complete blood count

Chemistry panel

Transaminase levels

BUN & creatinine

Urinalysis

RPR, VDRL, or treponema EIA

Tuberculin skin test or interferon-γ release assay

Toxoplasma IgG

Hepatitis A, B, & C serology

Pap smear

Fasting blood glucose & serum lipids if risk factors for CVD

Genotype resistance testing if viral load >1000 copies/mL

HLA-B*5701 if considering abacavir as part of initial regimen (N Engl J Med 2008;358:568)

Tropism testing if considering maraviroc as part of initial regimen

Pathophysiology

  • Day 0: exposure to HIV at the mucosal surface → Day 0–2: virus collected by dendritic cells, carried to lymph nodes → Day 4–11: HIV replication in CD4 cells, then released into the blood → Day 11 onward: viral spread to various organs (Ann Intern Med 1996;125:257)

Treatment & Follow-Up

  • Preferred initial regimens in treatment-naïve patients(as of March 27, 2012):
    • Efavirenz/tenofovir/emtricitabine
    • Raltegravir + tenofovir/emtricitabine
    • Ritonavir-boosted atazanavir + tenofovir/emtricitabine
    • Ritonavir-boosted darunavir + tenofovir/emtricitabine
  • Alternative regimens(as of March 27, 2012)
    • Efavirenz + abacavir/lamivudine
    • Rilpivirine/tenofovir/emtricitabine
    • Rilpivirine + abacavir/lamivudine
    • Raltegravir + abacavir/lamivudine
    • Ritonavir-boosted atazanavir + abacavir or zidovudine + lamivudine
    • Ritonavir-boosted darunavir + abacavir/lamivudine
    • Ritonavir-boosted fosamprenavir + [abacavir or zidovudine + lamivudine] or tenofovir/emtricitabine
    • Lopinavir/ritonavir + (abacavir or zidovudine + lamivudine) or tenofovir/emtricitabine

Table 35-3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
View Table||Download (.pdf)
Table 35-3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
MOA: Competes with natural substrates for incorporation into growing chains of viral RNA-dependent DNA polymerase (reverse ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close